Ellen Ritchie, MD, Hematology, New York, NY, NewYork-Presbyterian/Weill Cornell

EllenKellyRitchieMD

Hematology New York, NY

Hematologic Oncology

Associate Clinical Professor of Medicine, Weill Cornell Medical College

Dr. Ritchie is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ritchie's full profile

Already have an account?

Education & Training

  • New York Presbyterian Hospital
    New York Presbyterian HospitalFELLOWSHIP
  • New York Presbyterian Hospital
    New York Presbyterian HospitalRESIDENCY
  • Columbia University College of Physicians & Surgeons
    Columbia University College of Physicians & SurgeonsMEDICAL_SCHOOL

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1999 - 2022
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...
    Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloi...
    Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...
    Ellen K. Ritchie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • CPX-351 As First Intensive Therapy for Elderly Patients with AML 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML). 
    2019 ASCO Annual Meeting - 6/1/2019
  • Join now to see all

Authored Content

  • Clinical Trial Patient Shortage Will Hinder the Progress of AML Drug DevelopmentDecember 2018

Press Mentions

  • Astellas Presents New Data on XOSPATA® (Gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting
    Astellas Presents New Data on XOSPATA® (Gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual MeetingDecember 02, 2019
  • Understanding Rare Blood Cancers and Their Symptoms
    Understanding Rare Blood Cancers and Their Symptoms
  • Actress Spreads Awareness of Rare Blood Cancer
    Actress Spreads Awareness of Rare Blood CancerSeptember 04, 2017
  • Join now to see all

Professional Memberships

Hospital Affiliations